论文部分内容阅读
目的:研究肿瘤标志物及生化指标的联合检测对胸腔积液病因的诊断价值。方法:选取我院2015年3月~2016年3月收治的51例恶性胸腔积液患者作为观察组,选取同期在我院诊断的51例良性胸腔积液患者作为对照组。对两组患者实施肿瘤标志物及生化指标联合的方式进行检测。结果:观察组的癌胚抗原值为3.68±0.26μm/m L,腺苷脱氨酶的值为13.89±6.67U/L,对照组的癌胚抗原值为167.35±45.75μm/m L,腺苷脱氨酶的值为17.45±7.83U/L,两组在检测结果上的对比差异有统计学意义(P<0.05)。结论:采用肿瘤标志物及生化标志的联合检测方式,能够提高对各项指标检测的准确率,能够使医生根据病因为患者制定有针对性的治疗方案,具有一定的临床应用价值。
Objective: To study the diagnostic value of combined detection of tumor markers and biochemical indicators on the etiology of pleural effusion. Methods: Fifty-one patients with malignant pleural effusion admitted to our hospital from March 2015 to March 2016 were selected as the observation group and 51 patients with benign pleural effusion diagnosed in our hospital were selected as the control group. Two groups of patients to implement the combination of tumor markers and biochemical methods to detect. Results: The value of carcinoembryonic antigen in the observation group was 3.68 ± 0.26μm / m L, the value of adenosine deaminase was 13.89 ± 6.67U / L, the value of carcinoembryonic antigen in the control group was 167.35 ± 45.75μm / m L, The value of glycosaminodeaminase was 17.45 ± 7.83U / L, the difference between the two groups in the test results was statistically significant (P <0.05). Conclusion: The combined detection of tumor markers and biochemical markers can improve the accuracy of the detection of various indicators, enabling doctors to make targeted treatment programs based on the cause of the disease, and has certain clinical value.